Products
Lixudebart Biosimilar Monoclonal Antibody (Claudin-1) for Research
Cat No.: GMP-Bios-INN-1263
Anti-CLDN1 therapeutic antibody (Pre-made Lixudebart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lixudebart (development code ALE-F02) is a monoclonal antibody targeting claudin 1 (CLDN1). It is developed by Alentis Therapeutics for glomerulonephritis, hepatic fibrosis, and pulmonary fibrosis. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1263-1mg | 1mg | 3090 |
| GMP-Bios-INN-1263-10mg | 10mg | |
| GMP-Bios-INN-1263-100mg | 100mg | |
| GMP-Bios-INN-1263-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lixudebart biosimilar, Whole mAb, Anti-CLDN1 Antibody: Anti-Claudin 1/CLDN1/Claudin-1/Senescence-associated epithelial membrane protein therapeutic antibody |
| INN Name | Lixudebart |
| Target | CLDN1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | INSERM;The Mount Sinai Hospital;University of Strasbourg;Alentis Therapeutics |
| Conditions Approved | na |
| Conditions Active | Glomerulonephritis;Hepatic fibrosis;Pulmonary fibrosis;Renal fibrosis |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
